Hepion Pharmaceuticals Inc (HEPA)

[crudeoil24]

Hepion Pharmaceuticals Schedules Conference Call To Review Data From Phase 2a 'AMBITION' Clinical Trial Of CRV431 in NASH
4:05 pm ET September 10, 2021 (Benzinga) Print
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, today announced that it expects to release additional data from its Phase 2a ‘AMBITION' NASH clinical trial before the market opens on Monday, September 13, 2021. As previously disclosed, all primary endpoints were achieved in the trial.


Hepion is pleased to invite all interested parties to participate in a conference call and webcast at 8:30 a.m. ET on September 13, during which the previously disclosed AMBITION topline results, as well as the additional new data, will be discussed.

To participate telephonically, please dial [phone] (U.S.) or [phone] (international), conference ID 3568976, approximately 10 minutes prior to the start time. A live, listen-only webcast of the conference call, which will include accompanying slides, can be accessed by visiting the "Events" page of the "Investors" section at www.hepionpharma.com. An archive of the webcast will be available for approximately 90 days following the conclusion of the conference call.